Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iC9-GD2 CAR T cells in pediatric and young adult GD2+ tumors
2024-520436-15-00Phase 2Authorised
- Sponsor
- Ospedale Pediatrico Bambino Gesù
- Start
- Feb 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GD2-CART01 in neuroblastoma and Nonhematologic neoplasms, sponsored by Ospedale Pediatrico Bambino Gesù. Primary endpoint: Phase I safety and dose-limiting toxicity. Planned start Feb 2025; status: authorised.
02
Drugs
GD2-CART01
03
Conditions
neuroblastomaNonhematologic neoplasms
Beyond the preview
Go deeper on 2024-520436-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520436-15-00.